CoChat
Sign Up
Cited by 205Immunotherapy and Immune Responsesvaccines and immunoinformatics approachesChemical Synthesis and Analysis

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

The Peptide Vaccine of the Future

Open access
Nelde, Annika, Rammensee, Hans-Georg, Walz, Juliane S.·2021·Molecular & Cellular Proteomics
DOI 10.1074/mcp.r120.002309PMC PMC7950068
Open this paper in CoChat — free accountOpen PDF

Abstract

The approach of peptide-based anticancer vaccination has proven the ability to induce cancer-specific immune responses in multiple studies for various cancer entities. However, clinical responses remain so far limited to single patients and broad clinical applicability was not achieved. Therefore, further efforts are required to improve peptide vaccination in order to integrate this low-side-effect therapy into the clinical routine of cancer therapy. To design clinically effective peptide vaccines in the future, different issues have to be addressed and optimized comprising antigen target selection as well as choice of optimal adjuvants and vaccination schedules. Furthermore, the combination of peptide-based vaccines with other immuno- and molecular targeted therapies as well as the development of predictive biomarkers could further improve efficacy. In this review, current approaches in the development of peptide-based vaccines and critical implications for optimal vaccine design are discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/mcp.r120.002309

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 143

  1. Kucerova, 2016, Spontaneous regression of tumour and the role of microbial infection - possibilities for cancer treatment, Anticancer Drugs, 27, 269, 10.1097/CAD.0000000000000337 · DOI
  2. Hoption Cann, 2003, Dr William Coley and tumour regression: a place in history or in the future, Postgrad. Med. J., 79, 672, 10.1093/postgradmedj/79.938.672 · DOI
  3. Coley, 1910, The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus), Proc. R. Soc. Med., 3, 1
  4. Busch, 1866, Einfluss von Erysipel, Berliner Klin. Wschr., 3, 245
  5. Taefehshokr, 2020, Promising approaches in cancer immunotherapy, Immunobiology, 225, 151875, 10.1016/j.imbio.2019.11.010 · DOI
  6. Sahin, 2018, Personalized vaccines for cancer immunotherapy, Science, 359, 1355, 10.1126/science.aar7112 · DOI
  7. Roy, 2020, Breakthrough concepts in immune-oncology: cancer vaccines at the bedside, J. Leukoc. Biol., 108, 1455, 10.1002/JLB.5BT0420-585RR · DOI
  8. van Rooij, 2013, Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma, J. Clin. Oncol., 31, e439, 10.1200/JCO.2012.47.7521 · DOI · Paper page
  9. Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N. Engl. J. Med., 371, 2189, 10.1056/NEJMoa1406498 · DOI · Paper page
  10. Kloor, 2020, A Phase I/IIa trial of a frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers, Clin. Cancer Res., 10.1158/1078-0432.CCR-19-3517 · DOI
  11. Fang, 2020, A pan-cancer clinical study of personalized neoantigen vaccine monotherapy in treating patients with various types of advanced solid tumors, Clin. Cancer Res., 26, 4511, 10.1158/1078-0432.CCR-19-2881 · DOI
  12. Nelde, 2017, HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy, Oncoimmunology, 126, 2750
  13. Schenck, 2019, NeoPredPipe: high-throughput neoantigen prediction and recognition potential pipeline, BMC Bioinformatics, 20, 264, 10.1186/s12859-019-2876-4 · DOI
  14. Bjerregaard, 2017, MuPeXI: prediction of neo-epitopes from tumor sequencing data, Cancer Immunol. Immunother., 66, 1123, 10.1007/s00262-017-2001-3 · DOI
  15. Hundal, 2016, pVAC-Seq: a genome-guided in silico approach to identifying tumor neoantigens, Genome Med., 8, 11, 10.1186/s13073-016-0264-5 · DOI
  16. Bais, 2017, CloudNeo: a cloud pipeline for identifying patient-specific tumor neoantigens, Bioinformatics, 33, 3110, 10.1093/bioinformatics/btx375 · DOI
  17. Nielsen, 2010, MHC class II epitope predictive algorithms, Immunology, 130, 319, 10.1111/j.1365-2567.2010.03268.x · DOI
  18. Finn, 2018, Is it possible to develop cancer vaccines to neoantigens, what are the major challenges, and how can these be overcome? Neoantigens: nothing new in spite of the name, Cold Spring Harb. Perspect. Biol., 10, 10.1101/cshperspect.a028829 · DOI
  19. Bassani-Sternberg, 2016, Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry, Nat. Commun., 7, 13404, 10.1038/ncomms13404 · DOI · Paper page
  20. Müller, 2017, “Hotspots” of antigen presentation revealed by human leukocyte antigen ligandomics for neoantigen prioritization, Front. Immunol., 8, 1367, 10.3389/fimmu.2017.01367 · DOI
  21. Pearson, 2016, MHC class I-associated peptides derive from selective regions of the human genome, J. Clin. Invest., 126, 4690, 10.1172/JCI88590 · DOI
  22. Laumont, 2016, Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames, Nat. Commun., 7, 10238, 10.1038/ncomms10238 · DOI
  23. Erhard, 2018, Improved Ribo-seq enables identification of cryptic translation events, Nat. Methods, 15, 363, 10.1038/nmeth.4631 · DOI
  24. Parvizpour, 2019, In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens, Bioimpacts, 9, 45, 10.15171/bi.2019.06 · DOI
  25. Safavi, 2019, In silico analysis of transmembrane protein 31 (TMEM31) antigen to design novel multiepitope peptide and DNA cancer vaccines against melanoma, Mol. Immunol., 112, 93, 10.1016/j.molimm.2019.04.030 · DOI
  26. Qazilbash, 2017, PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies, Leukemia, 31, 697, 10.1038/leu.2016.254 · DOI
  27. Rammensee, 1999, SYFPEITHI: database for MHC ligands and peptide motifs, Immunogenetics, 50, 213, 10.1007/s002510050595 · DOI
  28. Reynisson, 2020, NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data, Nucleic Acids Res., 48, W449, 10.1093/nar/gkaa379 · DOI · Paper page
  29. Weinzierl, 2007, Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface, Mol. Cell. Proteomics, 6, 102, 10.1074/mcp.M600310-MCP200 · DOI
  30. Fortier, 2008, The MHC class I peptide repertoire is molded by the transcriptome, J. Exp. Med., 205, 595, 10.1084/jem.20071985 · DOI
  31. Bassani-Sternberg, 2015, Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation, Mol. Cell. Proteomics, 14, 658, 10.1074/mcp.M114.042812 · DOI
  32. Shraibman, 2019, Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma, Mol. Cell. Proteomics, 18, 1255, 10.1074/mcp.RA119.001524 · DOI
  33. Bilich, 2019, The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy, Blood, 133, 550, 10.1182/blood-2018-07-866830 · DOI
  34. Schuster, 2017, The immunopeptidomic landscape of ovarian carcinomas, Proc. Natl. Acad. Sci. U. S. A., 114, E9942
  35. Kowalewski, 2015, HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL), Proc. Natl. Acad. Sci. U. S. A., 112, E166, 10.1073/pnas.1416389112 · DOI
  36. Neidert, 2018, The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy, Acta Neuropathol., 135, 923, 10.1007/s00401-018-1836-9 · DOI
  37. Reustle, 2020, Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy, Genome Med., 12, 32, 10.1186/s13073-020-00731-8 · DOI
  38. Teck, 2020, Cancer testis antigen Cyclin A1 harbors several HLA-A∗02:01-restricted T cell epitopes, which are presented and recognized in vivo, Cancer Immunol. Immunother., 69, 1217, 10.1007/s00262-020-02519-6 · DOI
  39. Bilich, 2020, Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma, Blood Cancer J., 10, 24, 10.1038/s41408-020-0288-3 · DOI
  40. Heidenreich, 2017, Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8+ cytotoxic T cells, Haematologica, 102, e460, 10.3324/haematol.2017.167312 · DOI
  41. Walz, 2015, The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy, Blood, 126, 1203, 10.1182/blood-2015-04-640532 · DOI
  42. Freudenmann, 2018, Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry, Immunology, 154, 331, 10.1111/imm.12936 · DOI
  43. Marcu, 2019, The HLA ligand atlas. A resource of natural HLA ligands presented on benign tissues, bioRxiv
  44. Marcu, 2020, The HLA Ligand Atlas: a novel immuno-oncology resource for T-cell antigen discovery, J. Clin. Oncol., 10.1200/JCO.2020.38.15_suppl.3128 · DOI
  45. 2013, The genotype-tissue expression (GTEx) project, Nat. Genet., 45, 580, 10.1038/ng.2653 · DOI · Paper page
  46. Uhlén, 2015, Proteomics. Tissue-based map of the human proteome, Science, 347, 1260419, 10.1126/science.1260419 · DOI · Paper page
  47. Melssen, 2017, Vaccines targeting helper T cells for cancer immunotherapy, Curr. Opin. Immunol., 47, 85, 10.1016/j.coi.2017.07.004 · DOI
  48. Bijker, 2007, CD8+ CTL priming by exact peptide epitopes in incomplete Freund’s adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity, J. Immunol., 179, 5033, 10.4049/jimmunol.179.8.5033 · DOI
  49. Zwaveling, 2002, Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides, J. Immunol., 169, 350, 10.4049/jimmunol.169.1.350 · DOI
  50. Spitzer, 2017, Systemic immunity is required for effective cancer immunotherapy, Cell, 168, 487, 10.1016/j.cell.2016.12.022 · DOI · Paper page
  51. Hu, 2014, Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine, Cancer Immunol. Immunother., 63, 779, 10.1007/s00262-014-1551-x · DOI
  52. Giuntoli, 2002, Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function, Clin. Cancer Res., 8, 922
  53. Bos, 2010, CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes, Cancer Res., 70, 8368, 10.1158/0008-5472.CAN-10-1322 · DOI
  54. Maslak, 2018, Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia, Blood Adv., 2, 224, 10.1182/bloodadvances.2017014175 · DOI
  55. Rabu, 2019, Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells, Oncoimmunology, 8, 10.1080/2162402X.2018.1560919 · DOI
  56. Sayem, 2015, Identification of glypican-3-derived long peptides activating both CD8+ and CD4+ T cells; prolonged overall survival in cancer patients with Th cell response, Oncoimmunology, 5
  57. Pedersen, 2016, Immunogenicity of HLA class I and II double restricted influenza a-derived peptides, PLoS One, 11, 10.1371/journal.pone.0145629 · DOI
  58. Ohtake, 2014, Identification of novel helper epitope peptides of survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine, Immunol. Lett., 161, 20, 10.1016/j.imlet.2014.04.010 · DOI
  59. Daftarian, 2006, Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion, Vaccine, 24, 5235, 10.1016/j.vaccine.2006.03.079 · DOI
  60. Toes, 1996, Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction, Proc. Natl. Acad. Sci. U. S. A., 93, 7855, 10.1073/pnas.93.15.7855 · DOI
  61. Aichele, 1995, T cell priming versus T cell tolerance induced by synthetic peptides, J. Exp. Med., 182, 261, 10.1084/jem.182.1.261 · DOI
  62. Kast, 1993, Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination, Eur. J. Immunol., 23, 1189, 10.1002/eji.1830230534 · DOI
  63. Bijker, 2008, Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation, Eur. J. Immunol., 38, 1033, 10.1002/eji.200737995 · DOI
  64. Southwood, 1998, Several common HLA-DR types share largely overlapping peptide binding repertoires, J. Immunol., 160, 3363, 10.4049/jimmunol.160.7.3363 · DOI
  65. Walter, 2012, Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival, Nat. Med., 18, 1254, 10.1038/nm.2883 · DOI
  66. Hilf, 2019, Actively personalized vaccination trial for newly diagnosed glioblastoma, Nature, 565, 240, 10.1038/s41586-018-0810-y · DOI · Paper page
  67. Di Marco, 2017, Identification of immunogenic epitopes by MS/MS, Cancer J., 23, 102, 10.1097/PPO.0000000000000252 · DOI
  68. Peper, 2015, A combined approach of human leukocyte antigen ligandomics and immunogenicity analysis to improve peptide-based cancer immunotherapy, Cancer Immunol. Immunother., 64, 1295, 10.1007/s00262-015-1682-8 · DOI
  69. Mashishi, 2002, The ELISPOT assay: an easily transferable methods for measuring cellular responses and identifying T cell epitopes, Clin. Chem. Lab. Med., 40, 903, 10.1515/CCLM.2002.159 · DOI
  70. Freer, 2013, Intracellular cytokine detection by fluorescence-activated flow cytometry: basic principles and recent advances, Methods, 61, 30, 10.1016/j.ymeth.2013.03.035 · DOI
  71. Yoshimura, 2016, A phase 2 randomized controlled trial of personalized peptide vaccine immunotherapy with low-dose dexamethasone versus dexamethasone alone in chemotherapy-naive castration-resistant prostate cancer, Eur. Urol., 70, 35, 10.1016/j.eururo.2015.12.050 · DOI
  72. Shima, 2019, Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma, Cancer Sci., 110, 2378, 10.1111/cas.14106 · DOI
  73. Ravandi, 2018, Evaluating measurable residual disease in acute myeloid leukemia, Blood Adv., 2, 1356, 10.1182/bloodadvances.2018016378 · DOI
  74. Bilich, 2017, Definition and characterization of a peptide warehouse for the patient-individualized peptide vaccination study (iVAC-L-CLL01) after first line therapy of CLL, Blood, 130, 5346
  75. Slansky, 2020, Peptide mimotopes alter T cell function in cancer and autoimmunity, Semin. Immunol., 47, 101395, 10.1016/j.smim.2020.101395 · DOI
  76. Candia, 2016, On peptides and altered peptide ligands: from origin, mode of action and design to clinical application (immunotherapy), Int. Arch. Allergy Immunol., 170, 211, 10.1159/000448756 · DOI
  77. Li, 2013, Immune responses induced in HHD mice by multiepitope HIV vaccine based on cryptic epitope modification, Mol. Biol. Rep., 40, 2781, 10.1007/s11033-012-2202-y · DOI
  78. Sun, 2018, A modified HLA-A∗0201-restricted CTL epitope from human oncoprotein (hPEBP4) induces more efficient antitumor responses, Cell Mol. Immunol., 15, 768, 10.1038/cmi.2017.155 · DOI
  79. Zaremba, 1997, Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen, Cancer Res., 57, 4570
  80. Gladney, 2012, Heteroclitic peptides enhance human immunodeficiency virus-specific CD8+ T cell responses, Vaccine, 30, 6997, 10.1016/j.vaccine.2012.09.067 · DOI
  81. Salazar, 2000, Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of TC1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide, Int. J. Cancer, 85, 829, 10.1002/(SICI)1097-0215(20000315)85:6<829::AID-IJC16>3.0.CO;2-K · DOI
  82. Adegoke, 2015, Heteroclitic peptides increase proliferation and reduce evidence of human immunodeficiency virus-specific CD8+ T cell dysfunction, Viral Immunol., 28, 455, 10.1089/vim.2015.0036 · DOI
  83. Zom, 2016, TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients, Oncotarget, 7, 67087, 10.18632/oncotarget.11512 · DOI
  84. Deres, 1989, In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine, Nature, 342, 561, 10.1038/342561a0 · DOI
  85. Rauen, 2014, Enhanced cross-presentation and improved CD8+ T cell responses after mannosylation of synthetic long peptides in mice, PLoS One, 9, e103755, 10.1371/journal.pone.0103755 · DOI
  86. Vermaelen, 2019, Vaccine strategies to improve anticancer cellular immune responses, Front. Immunol., 10, 8, 10.3389/fimmu.2019.00008 · DOI
  87. Delves, 2000, The immune system. Second of two parts, N. Engl. J. Med., 343, 108, 10.1056/NEJM200007133430207 · DOI
  88. He, 2018, Peptide delivery systems for cancer vaccines, Adv. Ther., 1, 1800060, 10.1002/adtp.201800060 · DOI
  89. Aucouturier, 2002, Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines, Expert Rev. Vaccines, 1, 111, 10.1586/14760584.1.1.111 · DOI
  90. Varypataki, 2017, Efficient eradication of established tumors in mice with cationic liposome-based synthetic long-peptide vaccines, Cancer Immunol. Res., 5, 222, 10.1158/2326-6066.CIR-16-0283 · DOI
  91. Zhou, 2020, Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy, Biomaterials, 235, 119795, 10.1016/j.biomaterials.2020.119795 · DOI
  92. Mach, 2000, Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand, Cancer Res., 60, 3239
  93. Rausch, 2019, Results of a phase 1/2 study in metastatic renal cell carcinoma patients treated with a patient-specific adjuvant multi-peptide vaccine after resection of metastases, Eur. Urol. Focus, 5, 604, 10.1016/j.euf.2017.09.009 · DOI
  94. Hoeller, 2016, Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma, Cancer Immunol. Immunother., 65, 1015, 10.1007/s00262-016-1860-3 · DOI
  95. Krutzik, 2005, TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells, Nat. Med., 11, 653, 10.1038/nm1246 · DOI
  96. Ribi, 1979, Peptides as requirement for immunotherapy of the Guinea-pig line-10 tumor with endotoxins, Cancer Immunol. Immunother., 7, 43, 10.1007/BF00205409 · DOI
  97. Beutler, 2003, Innate immune sensing and its roots: the story of endotoxin, Nat. Rev. Immunol., 3, 169, 10.1038/nri1004 · DOI
  98. Qureshi, 1982, Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium, J. Biol. Chem., 257, 11808, 10.1016/S0021-9258(18)33836-5 · DOI
  99. Rastakhiz, 2019, Preparation of nanoliposomes linked to HER2/neu-derived (P5) peptide containing MPL adjuvant as vaccine against breast cancer, J. Cell Biochem., 10.1002/jcb.27090 · DOI
  100. Smith, 2018, Trial Watch: toll-like receptor agonists in cancer immunotherapy, Oncoimmunology, 7, 10.1080/2162402X.2018.1526250 · DOI
  101. Gouttefangeas, 2018, Personalized cancer vaccines: adjuvants are important, too, Cancer Immunol. Immunother., 67, 1911, 10.1007/s00262-018-2158-4 · DOI
  102. Sabbatini, 2012, Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients, Clin. Cancer Res., 18, 6497, 10.1158/1078-0432.CCR-12-2189 · DOI
  103. Rammensee, 2019, A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer, J. Immunother. Cancer, 7, 307, 10.1186/s40425-019-0796-5 · DOI
  104. van Montfoort, 2009, Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity, Proc. Natl. Acad. Sci. U. S. A., 106, 6730, 10.1073/pnas.0900969106 · DOI
  105. Krekorian, 2019, Imaging of T-cells and their responses during anti-cancer immunotherapy, Theranostics, 9, 7924, 10.7150/thno.37924 · DOI
  106. Haen, 2020, Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire, Nat. Rev. Clin. Oncol., 17, 595, 10.1038/s41571-020-0387-x · DOI
  107. Britten, 2013, The regulatory landscape for actively personalized cancer immunotherapies, Nat. Biotechnol., 31, 880, 10.1038/nbt.2708 · DOI
  108. Seol, 2019, A pilot prospective study of refractory solid tumor patients for NGS-based targeted anticancer therapy, Transl Oncol., 12, 301, 10.1016/j.tranon.2018.10.011 · DOI
  109. Parakh, 2017, Evolution of anti-HER2 therapies for cancer treatment, Cancer Treat. Rev., 59, 1, 10.1016/j.ctrv.2017.06.005 · DOI
  110. Narita, 2019, A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma, Neuro Oncol., 21, 348, 10.1093/neuonc/noy200 · DOI
  111. Rabsteyn, 2019, Abstract B124: personalized peptide vaccination based on patient-individual tumor-specific variants induces T-cell responses in pediatric patients, 10.1158/2326-6074.CRICIMTEATIAACR18-B124 · DOI
  112. Bui, 2006, Predicting population coverage of T-cell epitope-based diagnostics and vaccines, BMC Bioinformatics, 7, 153, 10.1186/1471-2105-7-153 · DOI
  113. Vita, 2015, The immune epitope database (IEDB) 3.0, Nucleic Acids Res., 43, D405, 10.1093/nar/gku938 · DOI
  114. Wick, 2018, GAPVAC-101: first-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma, J. Clin. Oncol., 36, 2000, 10.1200/JCO.2018.36.15_suppl.2000 · DOI
  115. Le Dieu, 2009, Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts, Blood, 114, 3909, 10.1182/blood-2009-02-206946 · DOI
  116. Nakata, 2018, Wilms tumour 1 peptide vaccine as a cure-oriented post-chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse, Br. J. Haematol., 182, 287, 10.1111/bjh.14768 · DOI
  117. Brown, 2020, Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence, Breast Cancer Res. Treat., 181, 391, 10.1007/s10549-020-05638-x · DOI
  118. Ahmad, 2004, Escape from immunotherapy: possible mechanisms that influence tumor regression/progression, Cancer Immunol. Immunother., 53, 844, 10.1007/s00262-004-0540-x · DOI
  119. Ramsay, 2008, Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug, J. Clin. Invest., 118, 2427
  120. Duan, 2020, Turning cold into hot: firing up the tumor microenvironment, Trends Cancer, 6, 605, 10.1016/j.trecan.2020.02.022 · DOI · Paper page
  121. Khleif, 2015, Strategies and designs for combination immune therapy, J. Transl. Med., 13, K7, 10.1186/1479-5876-13-S1-K7 · DOI
  122. MacKay, 2018, Combination of a T cell activating immunotherapy with immune modulators alters the tumor microenvironment and promotes more effective tumor control in preclinical models, Cancer Res., 78, 1761, 10.1158/1538-7445.AM2018-1761 · DOI
  123. Sharabi, 2015, Stereotactic radiation therapy augments antigen-specific PD-1–mediated antitumor immune responses via cross-presentation of tumor antigen, Cancer Immunol. Res., 3, 345, 10.1158/2326-6066.CIR-14-0196 · DOI
  124. Ali, 2016, Vaccines combined with immune checkpoint antibodies promote cytotoxic T-cell activity and tumor eradication, Cancer Immunol. Res., 4, 95, 10.1158/2326-6066.CIR-14-0126 · DOI
  125. Rini, 2016, IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial, Lancet Oncol., 17, 1599, 10.1016/S1470-2045(16)30408-9 · DOI
  126. Shi, 2008, Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma, Blood, 111, 1309, 10.1182/blood-2007-03-078535 · DOI
  127. Kowalewski, 2016, Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini, Blood Cancer J., 6, 10.1038/bcj.2016.14 · DOI
  128. Shraibman, 2016, HLA peptides derived from tumor antigens induced by inhibition of DNA methylation for development of drug-facilitated immunotherapy, Mol. Cell. Proteomics, 15, 3058, 10.1074/mcp.M116.060350 · DOI
  129. Nelde, 2018, HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy, Oncoimmunology, 128, 3234
  130. Chong, 2020, Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes, Nat. Commun., 11, 1293, 10.1038/s41467-020-14968-9 · DOI
  131. Bassani-Sternberg, 2010, Soluble plasma HLA peptidome as a potential source for cancer biomarkers, Proc. Natl. Acad. Sci. U. S. A., 107, 18769, 10.1073/pnas.1008501107 · DOI
  132. Shraibman, 2018, Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma, Mol. Cell. Proteomics, 17, 2132, 10.1074/mcp.RA118.000792 · DOI
  133. Ritz, 2017, Purification of soluble HLA class I complexes from human serum or plasma deliver high quality immuno peptidomes required for biomarker discovery, Proteomics, 17, 10.1002/pmic.201600364 · DOI
  134. Noguchi, 2010, Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination, Cancer Biol. Ther., 10, 1266, 10.4161/cbt.10.12.13448 · DOI
  135. Kanekiyo, 2018, IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides, Oncol. Rep., 39, 2385
  136. Kitahara, 2016, Prediction of the efficacy of immunotherapy by measuring the integrity of cell-free DNA in plasma in colorectal cancer, Cancer Sci., 107, 1825, 10.1111/cas.13085 · DOI
  137. Kijima, 2017, MicroRNA-6826 and-6875 in plasma are valuable non-invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer, Oncol. Rep., 37, 23, 10.3892/or.2016.5267 · DOI
  138. Suekane, 2020, Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients, Int. J. Oncol., 56, 1479
  139. Shindo, 2017, Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer, J. Exp. Clin. Cancer Res., 36, 36, 10.1186/s13046-017-0509-1 · DOI
  140. Murciano-Goroff, 2020, The future of cancer immunotherapy: microenvironment-targeting combinations, Cell Res., 30, 507, 10.1038/s41422-020-0337-2 · DOI
  141. Pelster, 2019, Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials, Ther. Adv. Med. Oncol., 10.1177/1758835919830826 · DOI
  142. Yoshida, 2011, Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: analysis of 500 cases, Oncol. Rep., 25, 57
  143. Feyerabend, 2009, Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer, Prostate, 69, 917, 10.1002/pros.20941 · DOI

Cited by

Sorted by citations

Metadata

Authors
Nelde, A., Rammensee, H.-G., & Walz, J. S.
Affiliations
  • Universitätsklinikum Tübingen (DE)
  • German Cancer Research Center (DE)
Corresponding author
Walz, Juliane S.
ORCID
Venue
Molecular & Cellular Proteomics
Publisher
Elsevier BV
Published
2021
Volume
20
Pages
100022
ISSN
1535-9476 (ISSN-L)
DOI
10.1074/mcp.r120.002309
PMC
PMC7950068
OpenAlex
W3113006303
Cited by
205
References
9
Citations by year
2026: 21 · 2025: 37 · 2024: 50 · 2023: 37 · 2022: 43 · 2021: 17
FWCI
2.30
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular & Cellular Proteomics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords
peptide vaccine, cancer immunotherapy, antigen selection, adjuvants, vaccination schedule, predictive biomarkers, combination therapy, vaccine design
MeSH terms
Adjuvants, Immunologic, Antigens, Humans, Neoplasms, Biomarkers, Cancer Vaccines, Vaccines, Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review